We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

61 hedge funds and large institutions have $382M invested in enGene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

7% more funds holding

Funds holding: 57 → 61 (+4)

3.82% less ownership

Funds ownership: 87.63% → 83.81% (-3.8%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

28% less capital invested

Capital invested by funds: $530M → $382M (-$148M)

Holders
61
Holders Change
+4
Holders Change %
+7.02%
% of All Funds
0.75%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
12
Increased
22
Reduced
14
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SL
Siren LLC
Connecticut
+$17.1M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$10.2M
3
VPC
Vestal Point Capital
New York
+$9.88M
4
BOCH
Blue Owl Capital Holdings
New York
+$9.4M
5
KCM
Kennedy Capital Management
Missouri
+$3.11M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$36.1M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$17.1M
3
EAM
Eventide Asset Management
Massachusetts
-$8.58M
4
B
Braidwell
Connecticut
-$6M
5
Morgan Stanley
Morgan Stanley
New York
-$5.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$1.58M +$2.07M +232,200 New
EC
27
Elmind Capital
New York
$1.43M – – –
DCM
28
DAFNA Capital Management
California
$1.28M +$211K +23,708 +14%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$1.18M -$3.46M -388,406 -69%
Two Sigma Investments
30
Two Sigma Investments
New York
$1.08M -$21.7K -2,443 -2%
Renaissance Technologies
31
Renaissance Technologies
New York
$1.06M +$1.2M +135,318 +651%
Jane Street
32
Jane Street
New York
$1.06M +$886K +99,547 +176%
Citadel Advisors
33
Citadel Advisors
Florida
$1.05M +$1.14M +128,559 +506%
ACM
34
ADAR1 Capital Management
Texas
$910K -$1.51M -170,000 -56%
TI
35
Trexquant Investment
Connecticut
$713K +$932K +104,697 New
XT
36
XTX Topco
Cayman Islands
$637K +$619K +69,574 +291%
Morgan Stanley
37
Morgan Stanley
New York
$590K -$5.63M -631,885 -88%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$445K +$262K +29,424 +82%
SEI Investments
39
SEI Investments
Pennsylvania
$409K +$534K +60,036 New
Squarepoint
40
Squarepoint
New York
$333K +$435K +48,899 New
Geode Capital Management
41
Geode Capital Management
Massachusetts
$264K +$87.1K +9,784 +34%
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$251K +$328K +36,873 New
QC
43
Quadrature Capital
United Kingdom
$230K -$132K -14,786 -30%
American Century Companies
44
American Century Companies
Missouri
$224K +$79.1K +8,881 +37%
HF
45
HRT Financial
New York
$218K -$288K -32,363 -50%
Northern Trust
46
Northern Trust
Illinois
$205K – – –
ECM
47
ExodusPoint Capital Management
New York
$181K +$237K +26,613 New
PFCS
48
Pale Fire Capital SE
Czech Republic
$163K – – –
JF
49
Jump Financial
Illinois
$147K +$73.3K +8,233 +61%
Raymond James Financial
50
Raymond James Financial
Florida
$143K +$9.25K +1,039 +5%
1
2
3

ENGN Hedge Fund Activity: Q1 2026 in Review

61 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q1 2026, worth a combined $382M — down 28% from $530M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ENGN positions and 8 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Siren LLC, adding an estimated $17.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $36.1M sold.

  • 61 institutional investors held enGene Therapeutics (ENGN) as of Q1 2026, up from 57 in Q4 2025.
  • Funds reported $382M of enGene Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
  • 12 funds opened new enGene Therapeutics positions in Q1 2026 and 8 closed out, a net change of +4 holders.
  • The largest enGene Therapeutics buyer in Q1 2026 was Siren LLC, an estimated $17.1M added.
  • The largest enGene Therapeutics seller in Q1 2026 was Cormorant Asset Management, an estimated $36.1M sold.

Based on aggregated 13F filings for Q1 2026.